Pfizer says a study shows its new drug reduces the risk of death from a rare heart disease to 30-percent.
The U.S. pharmaceutical giant says that, over a 30-month test period, the drug lowered the risk of death from an often-deadly condition.
In the study, 43-percent of people who were given a placebo died, compared to only 30-percent who received the new drug.
Pfizer presented the study earlier Monday at the European Society of Cardiology Congress in Munich.